Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

2Total

P 1 (1)

P 2 (1)

Unknown2

Terminated1

Clinical Trials (3)

Showing 3 of 3 trials

Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer

Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy

Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma

Showing all 3 trials